Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11412151rdf:typepubmed:Citationlld:pubmed
pubmed-article:11412151lifeskim:mentionsumls-concept:C0026896lld:lifeskim
pubmed-article:11412151lifeskim:mentionsumls-concept:C0054493lld:lifeskim
pubmed-article:11412151lifeskim:mentionsumls-concept:C0004368lld:lifeskim
pubmed-article:11412151pubmed:issue3lld:pubmed
pubmed-article:11412151pubmed:dateCreated2001-6-19lld:pubmed
pubmed-article:11412151pubmed:abstractTextSome myasthenia gravis (MG) patients have antibodies against skeletal muscle antigens in addition to the acetylcholine receptor (AChR). A major antigen for these antibodies is the Ca2+ release channel of the sarcoplasmic reticulum the ryanodine receptor (RyR). These antibodies are found mainly in MG patients with a thymoma MG and correlate with severe MG symptoms. The antibodies recognize a region near the N-terminus on the RyR, which seems to be of importance for RyR regulation. The antibodies cause allosteric inhibition of RyR function in vitro, inhibiting Ca2+ release from sarcoplasmic reticulum.lld:pubmed
pubmed-article:11412151pubmed:languageenglld:pubmed
pubmed-article:11412151pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11412151pubmed:citationSubsetIMlld:pubmed
pubmed-article:11412151pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11412151pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11412151pubmed:statusMEDLINElld:pubmed
pubmed-article:11412151pubmed:monthMarlld:pubmed
pubmed-article:11412151pubmed:issn0001-6772lld:pubmed
pubmed-article:11412151pubmed:authorpubmed-author:LundeP KPKlld:pubmed
pubmed-article:11412151pubmed:authorpubmed-author:AarliJ AJAlld:pubmed
pubmed-article:11412151pubmed:authorpubmed-author:SejerstedO...lld:pubmed
pubmed-article:11412151pubmed:authorpubmed-author:GilhusN ENElld:pubmed
pubmed-article:11412151pubmed:authorpubmed-author:MyglandAAlld:pubmed
pubmed-article:11412151pubmed:authorpubmed-author:SkeieG OGOlld:pubmed
pubmed-article:11412151pubmed:issnTypePrintlld:pubmed
pubmed-article:11412151pubmed:volume171lld:pubmed
pubmed-article:11412151pubmed:ownerNLMlld:pubmed
pubmed-article:11412151pubmed:authorsCompleteYlld:pubmed
pubmed-article:11412151pubmed:pagination379-84lld:pubmed
pubmed-article:11412151pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:meshHeadingpubmed-meshheading:11412151...lld:pubmed
pubmed-article:11412151pubmed:year2001lld:pubmed
pubmed-article:11412151pubmed:articleTitleAutoimmunity against the ryanodine receptor in myasthenia gravis.lld:pubmed
pubmed-article:11412151pubmed:affiliationDepartment of Neurology, University of Bergen, Bergen, Norway.lld:pubmed
pubmed-article:11412151pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11412151pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:11412151pubmed:publicationTypeReviewlld:pubmed